Short answer
Pacira BioSciences, Inc. (PCRX) filed an 8-K current report with the SEC on November 17, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.04 (Triggering Events That Accelerate or Increase a Direct Financial Obligation), Item 3.01 (Notice of Delisting), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $287.5 million of 2.125% convertible notes due 2029 remain outstanding.
- This filing includes Item 2.04 and Item 3.01, items that often signal trouble.
Pacira BioSciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $287.5 million of 2.125% convertible notes due 2029 remain outstanding
- Merger converts noteholders’ equity conversion right into cash based on $36.50 per share and the applicable conversion rate
- Company will not repurchase notes despite the merger-triggered fundamental change provisions
- Capped call transactions unwound for cash payments to Pacira, potentially reducing dilution protection post-merger
Item 1.02 · Termination of a Material Definitive Agreement
- Merger completion triggered repayment of $96,392.50 outstanding under Pacira’s Credit Agreement
- Credit Agreement and all lender commitments terminated on November 17, 2026
- Related liens will be released, eliminating secured obligations under the facility
- Termination removes the associated borrowing capacity and lender encumbrances post-merger
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Viatris completed its acquisition of Pacira on November 17, 2026, making Pacira a wholly owned subsidiary
- Cash consideration: $36.50 per share, with 32,929,780 shares tendered, representing approximately 66.46% ownership
- Approximately $1.69 billion funded share purchases and repayment of certain Pacira indebtedness, excluding fees and assumed cash
- Pacira shareholders’ remaining shares automatically converted into the right to receive $36.50 cash, subject to appraisal rights
- Equity awards converted into cash, while options with exercise prices at or above $36.50 received no consideration
Item 2.04 · Triggering Events That Accelerate or Increase a Direct Financial Obligation
- Item 2.04 contains no standalone event details
- Investors should assess the referenced Items 1.01, 1.02 and 2.01 for any obligations or transaction terms affecting Pacira BioSciences
Item 3.01 · Notice of Delisting
- Merger consummated, triggering Nasdaq trading halt before market open on November 17, 2026
- Form 25 delisting and Section 12(b) deregistration to remove Pacira shares from Nasdaq
- Planned Form 15 filing would terminate Section 12(g) registration and suspend SEC reporting obligations
- Shareholders should expect no continued public-market trading or regular SEC disclosures after the merger close
Item 3.03 · Material Modification to Rights of Security Holders
- Rights modification linked to the transactions and governance changes disclosed in Items 1.01, 2.01, 3.01, 5.01 and 5.03
- Investor impact depends on the referenced deal, listing, control and charter details elsewhere in the filing
Item 5.01 · Changes in Control of Registrant
- Viatris acquired 100% ownership of Pacira BioSciences upon merger completion on November 17, 2026
- Pacira shareholders’ control ended, with the company becoming a wholly owned Viatris subsidiary
- Transaction completed through a Delaware Section 251(h) tender-offer merger structure
Item 5.02 · Departure/Election of Directors or Officers
- Merger completion removed nine directors and six officers from Pacira’s board and management
- John Miraglia and Michael Rainerman assumed officer and director roles at the surviving corporation
- Leadership transition reflects control passing to the merger entity, with governance now aligned to the new ownership structure
- Investor focus: execution under the new leadership and continuity of Pacira’s operations post-merger
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Merger-triggered restatement of Pacira’s certificate of incorporation and bylaws effective at closing
- New governing documents replace prior versions, potentially changing shareholder rights and corporate governance
- Full Third A&R Certificate and Fourth A&R Bylaws filed as Exhibits 3.1 and 3.2
Item 7.01 · Regulation FD Disclosure
- Merger closing triggers a Common Stock Change Event under the Notes
- Holders notified of a Make-Whole Fundamental Change, potentially affecting conversion economics
- Fundamental Change designation may activate noteholder rights under the indenture
- Exempted Fundamental Change classification may limit certain change-of-control protections
Item EX-99.1 · Exhibit EX-99.1
- Viatris transaction closed November 17, 2026, converting Pacira into a wholly owned subsidiary and ending common-stock ownership
- Convertible notes now convert only into cash, based on $36.50 per share and the applicable conversion rate
- Make-whole conversion window runs through January 8, 2027, with conversion value $1,103.8914 per $1,000 note
- Make-whole value includes 4.9684 additional shares, versus $922.5448 per $1,000 after the window
- Pacira will not repurchase notes, making the January 8 deadline critical for holders seeking the enhanced conversion value
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pacira BioSciences, Inc. 8-K filings
Get the next PCRX 8-K as it lands
Follow PCRX for push alerts, or ask the research agent what this filing means.